Tempus AI Growth Outlook Boosted By Higher ASPs, Pharma Contracts, Analyst Says
1. BTIG analyst maintains Buy rating for TEM with a $96 price target. 2. TEM's revenue rose 84.7% year-over-year, reaching $334.21 million. 3. Adjusted loss per share improved to 11 cents from a 17 cents estimate. 4. Revenue guidance for FY25 increased to $1.265 billion from $1.260 billion. 5. Analyst expects growth from new pharma contracts and higher-priced tests.